Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Obesity-induced CYP2E1 activity in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Higher chlorzoxazone clearance in obese children compared with nonobese peers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Development of one paediatric and one neonatal formulary list in hospital settings

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hypoxia in individuals with type 1 diabetes and macroalbuminuria is associated with autonomic dysfunction

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock?

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

View graph of relations

Aims: Type 1 diabetes can be complicated with neuropathy that involves immune-mediated and inflammatory pathways. Glucagon-like peptide-1 receptor agonists such as liraglutide, have shown anti-inflammatory properties, and thus we hypothesized that long-term treatment with liraglutide induced diminished inflammation and thus improved neuronal function. Methods: The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy. They were randomly assigned (1:1) to receive either liraglutide or placebo. Titration was 6 weeks to 1.2–1.8 mg/d, continuing for 26 weeks. The primary endpoint was change in latency of early brain evoked potentials. Secondary endpoints were changes in proinflammatory cytokines, cortical evoked potential, autonomic function and peripheral neurophysiological testing. Results: Thirty-nine patients completed the study, of whom 19 received liraglutide. In comparison to placebo, liraglutide reduced interleukin-6 (−22.6%; 95% confidence interval [CI]: −38.1, −3.2; P =.025) with concomitant numerical reductions in other proinflammatory cytokines. However neuronal function was unaltered at the central, autonomic or peripheral level. Treatment was associated with −3.38 kg (95% CI: −5.29, −1.48; P <.001] weight loss and a decrease in urine albumin/creatinine ratio (−40.2%; 95% CI: −60.6, −9.5; P =.02). Conclusion: Hitherto, diabetic neuropathy has no cure. Speculations can be raised whether mechanism targeted treatment, e.g. lowering the systemic level of proinflammatory cytokines may lead to prevention or treatment of the neuroinflammatory component in early stages of diabetic neuropathy. If ever successful, this would serve as an example of how fundamental mechanistic principles are translated into clinical practice similar to those applied in the cardiovascular and nephrological clinic.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
Issue number11
Pages (from-to)2512-2523
Number of pages12
Publication statusPublished - Nov 2019

Bibliographical note

© 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

    Research areas

  • anti-inflammation, diabetic neuropathy, glucagon-like peptide-1 agonist, interleukin-6, liraglutide

ID: 57712886